Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy

BackgroundHuman epidermal growth factor receptor 2(HER-2) is the most prominent therapeutic target for gastric (G)/gastroesophageal junction (GEJ) cancer. Guidelines recommend its use for treating G/GEJ cancers. However, targeted therapy did not significantly improve survival outcomes compared to th...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Huanhuan Li, Chao Ren, Donghai Cui, Tao Wu, Zhiyong Nie
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Subjects:	HER-2 immunotherapy neoadjuvant therapy gastric cancer gastroesophageal junction adenocarcinoma
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1555074/full